Innoviva Inc. (INVA) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (75% profit margin, 15% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-01, Innoviva Inc. (NASDAQ: INVA) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $21.31 (+0.90% 1D, market cap $1.54B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 20/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INVA ranks #45 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INVA carries a Roarable B (75/100 RQD), trailing P/E of N/A, gross margin of 74.8%, and ROIC of 14.7%. By comparison, ETON (Eton Pharmaceuticals Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC -0.9%, cap $1.53B) and GPCR (Structure Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).
Per INVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001080014), Innoviva Inc. generated $411.3M in revenue (+14.7% YoY), $0 in net income, and $195.8M in free cash flow against $1.64B in total assets and $257.7M in total debt. Key quantitative strengths: Strong cash generator (75% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 47% of 52W Range • RSI-14 at 53.4 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 47.6% FCF Margin ($195.8M FCF) & 74.8% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)
Even with a 75/100 (B) score, INVA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 72.3% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($20.99) or 200D SMA ($21.89) invalidates the momentum regime and cuts Target Base ($22.94) toward Bear Floor ($17.47).
Innoviva Inc. (INVA) advanced +0.90% to $21.31, trading at 47% of its 52-week range ($17.84 – $25.15). High-quality cash engine (75% profit margin, 15% return on capital) with steady institutional support.
AbbVie (ABBV) delivered earnings and revenue surprises of +2.14% and +0.20%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Lilly (LLY) delivered earnings and revenue surprises of +39.03% and +10.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Innoviva (INVA) fits the Decent Value screen with low valuation, strong balance sheet, high margins, and attractive growth potential for value investors.
WALTHAM, Mass., October 19, 2026--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today it will present data from four abstracts at IDWeek 2026, the annual meeting of the I
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +14.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INVA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INVA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Innoviva Inc. (INVA) ranks #45 by composite RQD confidence (75/100, grade B) and #302 by equity capitalization ($1.54B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently leads its immediate peer cohort in composite quantitative strength at 75/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INVA
ACTIVE
Innoviva Inc. | B | 75/100 | — | 74.8% | 14.7% | +0.90% | $1.54B | Benchmark Subject |
| ETON Eton Pharmaceuticals Inc. | C | 62/100 | — | 53.5% | -0.9% | +3.61% | $1.53B | /eton-vs-inva → |
| GPCR Structure Therapeutics Inc. | D- | 42/100 | — | — | -19.5% | +2.14% | $1.56B | /gpcr-vs-inva → |
| PAHC Phibro Animal Health Corporation (Class A) | C+ | 68/100 | 32.7x | 30.9% | 9.9% | +2.59% | $1.58B | /pahc-vs-inva → |
| TYRA Tyra Biosciences Inc. | D- | 41/100 | — | — | -35.0% | -1.24% | $1.48B | /tyra-vs-inva → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Innoviva Inc. (INVA) reported GAAP revenue of $411.3M (+14.7% vs. FY2024 revenue of $358.7M , and +32.5% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $196.9M, and free cash flow of $195.8M (+3.9% YoY). On the balance sheet, INVA closed FY2025 with $1.64B in total assets against $257.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $411.3M | $0 | $196.9M | $195.8M | $1.64B | $257.7M |
| FY2024 (FY) | 2024-12-31 | $358.7M | $0 | $188.7M | $188.4M | $1.30B | $256.3M |
| FY2023 (FY) | 2023-12-31 | $310.5M | $0 | $141.1M | $141.1M | — | — |
As of 2026-11-01, Innoviva Inc. (NASDAQ: INVA) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $21.31 (+0.90% 1D, market cap $1.54B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 20/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INVA ranks #45 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INVA carries a Roarable B (75/100 RQD), trailing P/E of N/A, gross margin of 74.8%, and ROIC of 14.7%. By comparison, ETON (Eton Pharmaceuticals Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC -0.9%, cap $1.53B) and GPCR (Structure Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).
Per INVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001080014), Innoviva Inc. generated $411.3M in revenue (+14.7% YoY), $0 in net income, and $195.8M in free cash flow against $1.64B in total assets and $257.7M in total debt. Key quantitative strengths: Strong cash generator (75% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
INVA last traded at $21.31 (+0.90% on volume of 626,944 shares), positioning the stock +1.52% above its 50-day simple moving average ($20.99) and -2.65% below its 200-day simple moving average ($21.89). Across its 52-week range of $17.84 to $25.15, INVA sits at the 47.5% percentile with a 14-day RSI of 53.4 (NEUTRAL RANGE) and an implied next-earnings move of ±4.7% ($20.31 to $22.31).
Why INVA Stock advanced +0.90% Today — RQD Quant Desk Flash. High-quality cash engine (75% profit margin, 15% return on capital) with steady institutional support.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.